Ranbaxy gets temporary FDA nod
Posted on July 31, 2005
Filed Under Uncategorized
RANBAXY Laboratories Ltd has received tentative approval from the US Food and Drug Administration to manufacture and market glimepiride tablets, 3 mg and 6 mg used for treatment of diabetes.
The total annual market sales for Aventis Pharmaceuticals’ Amaryl tablets were $336.6 million. Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with non-insulin-dependent (Type II) diabetes mellitus whose hyperglycemia cannot be controlled by diet and exercise alone.
Comments
Leave a Reply